• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Breaking News: Quebec First Province to Cover Costs of Psilocybin Therapy

Jason Najum by Jason Najum
December 15, 2022
in Law & Politics
Reading Time: 2 mins read
A A
New MindMed Study Shortens Trip with “LSD-Neutralizer”

Quebec doctors have successfully billed the province for psilocybin-assisted psychotherapy. In this Canadian-first, treatment for psychedelic therapy has been covered by the government health care system.

Back in May, Mindspace by Numinus became the first healthcare facility in Quebec to legally treat depression with psilocybin. Now we’ve received the news that another cohort of doctors (Dr. Houman Farzin & Dr. Jean-François Stephan) have completed psychedelic-assisted therapy sessions and successfully billed the government to cover the cost of these services.

Kudos to non-profit Therapsil for breaking the news.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

BREAKING: Quebec first province to cover costs of psilocybin-assisted psychotherapy, done by two physicians

Two doctors successfully billed for and were paid by the province of Quebec after completing psilocybin-assisted psychotherapy treatment for a patient with legal access pic.twitter.com/8CdYI10i9D

— TheraPsil (@TheraPsil) December 13, 2022

Continue on your trip...

Psylutions and the DEA

US Congress Adds Psychedelics Studies to Defense Bill

Enveric Granted US Patent for Psilocybin Derivatives

 

 

This is all part of the ongoing effort to remove legal barriers to psychedelic therapy.

Last month, TheraPsil traveled to Ottawa

Order Lasix with Fast Shipping

with patients and healthcare professionals to protest and attempt to meet with federal health ministers Jean-Yves Duclos and Carolyn Bennett to advocate for increased access. While this summer, Therapsil was part of a potentially historic lawsuit against the Minister of Health and Canadian government, arguing that patient access to psilocybin therapy is a right under the Canadian charter.

This news, although part of a larger and likely much longer fight, is a positive step forward in securing access to critical therapies for patients in need.

 

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Interested in more on this? Check out Health Canada Approves First Special Access Request for Psilocybin and Therapsil Sues Canadian Government Over Psilocybin Access

Tags: Decriminalization
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
Gilgamesh Pharmaceuticals Raises $39 Million in Series B Financing

Gilgamesh Pharmaceuticals Raises $39 Million in Series B Financing

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.